GlassScriptPhysician profile
Koshnaf Antar
NPI 1720194152
$9,440.33
in general payments reported to CMS, 2019-2025
27 companies · $2,071 in 2025
The $2,071 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $220 · 2021: $411 · 2022: $1,182 · 2023: $2,249 · 2024: $2,373 · 2025: $2,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,429 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,428.99 |
| Education | $263.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,440.49 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,213.98 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $1,196.33 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $981.02 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $916.38 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $638.12 | 2022-2025 | |
| Pfizer INC. | $631.85 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $454.88 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $431.17 | 2022-2025 | Benlysta |
| Ucb, INC. | $310.54 | 2019-2025 | Cimzia, Bimzelx |
| Alexion Pharmaceuticals, INC. | $212.10 | 2023-2025 | Strensiq |
| Radius Health, INC. | $171.48 | 2019-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $106.35 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $99.98 | 2023 | Idacio |
| Celgene Corporation | $91.14 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $82.76 | 2019 | |
| Organon LLC | $77.00 | 2023-2025 | Hadlima, Renflexis |
| Mallinckrodt Hospital Products INC. | $76.55 | 2023-2024 | Acthar |
| Antares Pharma, INC. | $72.96 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $69.37 | 2024-2025 | Orencia |
| Scilex Pharmaceuticals INC. | $33.95 | 2024 | |
| Amarin Pharma, INC. | $29.49 | 2020 | |
| Kyowa Kirin, INC. | $27.32 | 2024 | Crysvita |
| Sobi, INC | $24.61 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.03 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2025 | |
| Mallinckrodt Enterprises LLC | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Koshnaf Antar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.